NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Septerna, Inc. (SEPN) Stock Analysis

Septerna, Inc. (SEPN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

SEPN

$40.76

+$1.41 (+3.58%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SEPN with… →

SEPN Key Statistics

As of Oct 21, 2026
Trading
Open
$39.57
Previous Close
$39.35
Day's Range
39.00–41.37
52-Week Range
17.55–51.10
Volume
286.39K
Valuation
Market Cap
$1.90B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
19.24
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.54
Financials (FY)
Revenue (FY)
$45.95M+4,174.51%
Net Income (FY)
−$48.88M
Profit marginThe share of revenue left as profit after all costs and taxes.
−24.51%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
46.68M
1-Year Return
+91.27%
Dividend and dates
Earnings Date
November 9, 2026estimated
Avg Volume
387.66K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, SEPN closed at $40.76, +91.27% over 1 year.

Septerna, Inc. (SEPN) has a market capitalization of $1.90B.

In fiscal 2025, SEPN reported revenue of $45.95M.

SEPN Stock Return by Calendar Year

Septerna, Inc. (SEPN) return since Oct 2024: what $10,000 became

1 year
$10,000 $19,127
+91.27%
Since Oct 2024
$10,000 $19,047
+90.47%

If you had invested $10,000 in Septerna, Inc. (SEPN) at the close on October 25, 2024, the earliest close on record here, it would have been worth $19,047 at the close on October 21, 2026: +90.47% in total, +38.29% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+46.20%
2025+21.75%
2024 (partial year)+7.01%

As of October 21, 2026.

SEPN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$45.95M−$48.88M−106.4%
2024$1.08M−$71.80M−6,678.9%
2023$151.00K$4.18M2,768.2%
2022$0.00−$27.68M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$45.95M—−$80.80M−$48.88M−106.4%
2024$1.08M—−$80.82M−$71.80M−6,678.9%
2023$151.00K—−$45.55M$4.18M2,768.2%
2022$0.00—−$27.97M−$27.68M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SEPN Valuation vs Biotechnology Median

Median of 608 stocks
MetricSEPNBiotechnology medianvs median
P/S ratio19.2413.3045% above
Profit margin−24.51%−38.31%13.8 pts above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 10 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Septerna, Inc. (SEPN) carries a market capitalisation of $1.90B. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 123 employees.

Over the past 52 weeks the price has ranged from $17.55 to $51.10. SEPN last closed at $40.76 on October 21, 2026. That is +$1.41 (+3.58%) against the previous close. The latest close sits 132.25% above that 52-week low.

Financial Health

In fiscal 2025, Septerna, Inc. reported revenue of $45.95M. Against the prior fiscal year total of $1.08M, that is a change of +4,174.51%. The same year closed with a net loss of $48.88M. The reported profit margin is −24.51%. That is 13.8 percentage points above the Biotechnology median of −38.31%. Earnings per share on a trailing basis come to −0.54.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $45.95M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 19.24 times revenue. On price-to-sales that is 44.68% above the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

Daily returns over the trailing 2 years annualize to a volatility of 89.38%. The trailing one-year total return is +91.27%. The stored price history starts on October 25, 2024, and the total return since then is +90.47%.

Growth & Income

The record shows no dividend for SEPN.

The record holds one complete calendar year, 2025, which returned +21.75%. 2026 is still running; the total return is +46.20% year to date.

Peer Comparison

Septerna, Inc. (SEPN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Septerna, Inc. SEPN $1.90B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Septerna, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Septerna, Inc.

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.

Visit website →